Mutations of the rpoB gene conferring resistance to rifampin were analyzed in 40 methicillin-resistant Staphylococcus aureus isolates obtained from six countries. Interestingly, the majority of clinical isolates showed multiple mutations within rpoB. The amino acid substitution 481His3Asn was the most prevalent one, capable of conferring low-level resistance on its own. Cross-resistance to rifampin, rifabutin, and rifapentine was demonstrated for all mutants identified. The level of resistance to rifamycins correlated with both the mutation position and type of amino acid substitution.
Multiresistance as a common feature in methicillin-resistant Staphylococcus aureus (MRSA) is a growing problem not only in hospital settings (5, 10, 22) . Glycopeptides are the antibiotics of choice in the treatment of infections caused by MRSA (15) . A combination therapy, however, with an antibiotic such as rifampin that reveals strong activity and good tissue penetration often is required to reach deep-seated infections effectively (6, 9, 16) . Rifampin acts by inhibiting bacterial RNA polymerase (23) . Previous studies on other bacteria provide evidence that mutations in rpoB, the gene which encodes the ␤ subunit of RNA polymerase, are responsible for rifampin resistance (Rif r ) (2, 8, 12, 17, 18, 20) . By using pairs of isogenic S. aureus isolates gathered before and after acquisition of resistance under rifampin therapy, Aubry-Damon et al. recently demonstrated the occurrence of amino acid substitutions within a short conserved region of the ␤ subunit and correlated the level of rifampin resistance with the mutations involved (2).
The present study was aimed at determining the distribution of mutations in the rpoB gene in clinical isolates of rifampinresistant MRSA as well as correlating the MICs of rifampin, rifabutin, and rifapentine with the locations and nature of the amino acid substitutions.
A total of 35 Rif r MRSA clinical isolates and five in vitro mutants generated from two rifampin-susceptible (Rif s ) epidemic MRSA strains were analyzed in this study. Fifteen of the Rif r MRSA isolates were furnished by laboratories in the United States, France, Italy, Poland, and Slovenia, whereas 20 of the Rif r initial isolates were obtained between 1993 and 1998 from German hospitals. All MRSA isolates were analyzed by pulsed-field gel electrophoresis as described previously (24) . Resistance to rifampin (Sigma, Deisenhofen, Germany), rifabutin (Pharmacia-Upjohn, Milan, Italy), and rifapentine (Hoechst Marion Roussel, Kansas, Mo.) was determined by the agar dilution method with Mueller-Hinton agar (Oxoid, Basingstoke, England) with an inoculum of 10 4 CFU per spot. Two oligonucleotide primers (Life Technologies, Eggenstein, Germany), rpoB1 (5Ј-ACC GTC GTT TAC GTT CTG TA) and rpoB2 (5Ј-TCA GTG ATA GCA TGT GTA TC), were designed to amplify and sequence a 460-bp PCR fragment encompassing clusters I and II of the rifampin resistance mutation sites of the S. aureus rpoB gene (1). Amplification was performed on a Gene Amp PCR system 2400 (Perkin-Elmer, Weiterstadt, Germany) under standard conditions. Direct sequencing of purified PCR products was carried out by using a dye reaction terminator cycle sequencing kit (PE Applied Biosystems, Weiterstadt, Germany) according to the protocol described by the manufacturer. Amplified DNA was sequenced in both directions by using the 310 genetic analyzer (Perkin-Elmer).
All MRSA isolates were characterized with regard to their genotypes and the MICs of rifampin, rifabutin, and rifapentine as shown in Table 1 . Comparable MICs of rifampin and rifapentine could be demonstrated for all MRSA isolates, whereas the MICs of rifabutin generally were two to eight times lower. The degree of resistance allowed classification of the strains in the categories of low-level resistance (MICs, 1 to 4 g/ml) and high-level resistance (MICs, Ն8 g/ml). Restriction analysis of chromosomal DNA demonstrated the unrelatedness of the majority of isolates and revealed 19 different genotypes, with MRSA T38 and T23 representing the southern and northern German epidemic strains, respectively (Fig. 1) . Sequence analysis of 40 MRSA isolates from six countries revealed missense mutations in a short region of the rpoB gene equivalent to clusters I and II of Escherichia coli (18) (Fig. 2) . Twelve mutational changes at 10 positions were identified, with 473Ala3Thr representing a new mutation site. New amino acid substitutions, 465Gln3Arg, 466Leu3Ser, 468Gln3Lys, and 477Ala3Thr in cluster I and 527Ile3Met and 529Ser3Leu in cluster II, were described, thereby emphasizing the high variability of these amino acid positions (2, 4, 7, 8, (18) (19) (20) (21) . Sequence findings allowed the categorization of all of the rifampin-resistant MRSA isolates into 12 different genotypes with respect to the mutations involved (Table 2) . Despite the different geographical origins of the isolates (Table 1) , codon 481 was mutated on 32 separate occasions, which indicates a central role of this amino acid. All in vivo isolates that demonstrated two or three amino acid changes exhibited highlevel resistance. Interestingly enough, all of these isolates showed the mutational change 481His3Asn, which is capable of conferring low-level resistance on its own, thereby indicating a two-step resistance mechanism in vivo to high-level resistance within these isolates. High-level resistance in vivo, however, was not demonstrated to occur through multiple mutations alone. The single amino acid substitution 468Gln3Lys also causes high-level resistance.
Generation of Rif r mutants in vitro resulted in both of the phenotypes observed. Low-level resistance followed by a second mutation leading to high-level resistance also was demonstrated in vitro (Table 2) . Rif s strain T23 cultured on 0.0625 g of rifampin-supplemented agar per ml revealed a new low-level resistant mutant with the amino acid substitution 471Asp3Tyr (T23a). When, in turn, T23a was plated on 64 g of rifampin per ml, a new mutant readily acquired a second mutation, 486Ser3Leu, resulting in high-level resistance (T23aa). Rif s strain T38 was cultured on rifampin-supplemented agar at concentrations of 0.0625 and 64 g/ml, and two single highlevel resistance mutations were found with 468Gln3Lys (T38a) and 481His3Tyr (T38b), respectively. A substitution at amino acid position 481 within isolates T38b and T382 conferred low-or high-level resistance depending on the nature of the new amino acid (Table 2) . T4  2  T25  1  T115  2  T211  2  CAT3AAT  481His3Asn  T236  2  T382  2  T403  2  T404  2   T36  512  T59  512  T66  512  CAT3AAT  481His3Asn   T118  256  TTA3TCA  466Leu3Ser   T166  512   T112  256  T161  256  T212  256  T248  256  T249  256  T250  256  T262  512  CAT3AAT  481His3Asn  T264  512  TCA3TTA  529Ser3Leu  T295  256  T296  256  T297  256  T398  128  T399  256  T401  512  T402  128   T397  512  CAT3AAT  481His3Asn  T400  256  ATT3ATG  527Ile3Met   T20  512  CAT3AAT  481His3Asn  CAA3CGA  465Gln3Arg  TCA3TTA  529Ser3Leu   T46  1,024  CAT3AAT  481His3Asn  GCA3ACA  473Ala3Thr  GCT3ACT  477Ala3Thr   T109  Ͼ1,024  T113  512  CAA3AAA  468Gln3Lys  T124  512   T38a  512  CAA3CTT  468Gln3Leu   T38b  512  CAT3TAT  481His3Tyr   T23a  4  GAC3TAC  471Asp3Tyr   T23aa  Ͼ1,024  GAC3TAC  471Asp3Tyr  TCA3TTA  486Ser3Leu   T23b  1,024  TCA3TTA  486Ser3Leu a The mutations listed are for all strains within a grouping. Base changes are underlined.
b The amino acid changes listed are for all strains within a grouping.
With respect to the pharmacokinetics of rifampin (27) and the findings presented in this study, we agree with the suggestion made by Aubry-Damon et al. (2) to revise the breakpoints for rifampin set by the National Committee for Clinical Laboratory Standards (13) . Accordingly, new breakpoints of Յ0.5 and Ն8 g/ml for the categorization of S. aureus relative to rifampin seem reasonable.
The goal of the present study was to elucidate the distribu- (1-3, 11, 14, 25, 26) . The amino acid alignment is presented in a single-letter code. Asterisks symbolize identity to E. coli sequence. Positions involved in rifampin resistance are marked; mutations are indicated by downward-pointing arrows; insertions are indicated by upside-down triangles; and deletions are underlined. The new Rif r mutation site found in this study is indicated by a double downward-pointing arrow. Amino acid substitutions involved in Rif r found in this study are presented in italics. Amino acid substitutions not previously described are indicated in boldface.
tion of mutations within the rpoB gene in rifampin-resistant MRSA and to assess the in vitro effectiveness of different rifamycins against these isolates. By presenting seven new mutations, the study confirms that rpoB mutations are responsible for the common Rif r phenotype in MRSA and that the level of resistance to any rifamycin is dependent on both the type and the location of the mutation within the rpoB gene. The occurrence of multiple mutations within rpoB for S. aureus is first described in this study. Their presence might be explained by the epidemic nature of many MRSA strains and, consequently, the frequent exposure of these strains to rifampin chemotherapy. Finally, we were able to demonstrate that the mutations involved confer cross-resistance to rifampin, rifabutin, and rifapentine, thereby indicating that these antibiotics are likely to exhibit comparable effectiveness in the treatment of S. aureus infection.
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